期刊文献+

年龄相关性黄斑变性及息肉状脉络膜血管病变患者房水中不同亚型VEGF含量的测定 被引量:2

Concentrations of different isoforms of VEGF in aqueous humor in patients with neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
下载PDF
导出
摘要 背景 息肉状脉络膜血管病变(PCV)是湿性年龄相关性黄斑变性(nAMD)的一个亚型还是独立于nAMD一种病变目前仍有不同的观点,而两种疾病的治疗效果可能不同.抗血管内皮生长因子(VEGF)在nAMD的治疗中发挥重要作用,但由VEGF可变剪切而产生的促新生血管生成VEGF(VEGFxxx)家族和抑新生血管VEGF(VEGFxxxb)家族,两者功能相反,其在nAMD和PCV中的表达及作用尚不清楚. 目的 检测和比较VEGFxxx家族和VEGFxxxb家族在nAMD患者和PCV患者房水中的变化及其意义. 方法 收集2013年3-12月在北京大学人民医院眼科确诊的nAMD患者34例及PCV患者26例,同期纳入16例年龄相关性白内障患者作为对照.收集被检者前房水0.1 ml,采用酶联免疫吸附试验(ELISA)测定前房水中VEGF及VEGF165b质量浓度,比较3组患者房水中VEGF及VEGF165b质量浓度的差异. 结果 nAMD组、PCV组、对照组患者房水中VEGF质量浓度分别为(4 210.00±998.40)、(387.00±51.31)和(377.40±69.97) pg/ml,组间总体差异有统计学意义(F=12.851,P=0.000).nAMD组、PCV组、对照组VEGF165b质量浓度分别为(205.50±12.59)、(159.40± 16.25)、(347.90±29.18) pg/ml,组间总体比较差异有统计学意义(F=23.752,P=0.000).与对照组比较,nAMD组患眼房水中VEGF质量浓度升高,VEGF165b质量浓度下降,PCV组患眼房水中VEGF165b表达下降,差异均有统计学意义(均P=0.000),但PCV组与对照组患眼房水中VEGF含量差异无统计学意义(P=0.992).nAMD组较PCV组房水中VEGF质量浓度升高,差异有统计学意义(P=0.001),但两组间VEGF165b质量浓度差异无统计学意义(P=0.097). 结论 nAMD患者前房水中的VEGF质量浓度明显高于PCV患者和年龄相关性白内障患者,nAMD患者与PCV患者房水中VEGF165b质量浓度接近,但均低于年龄相关性白内障患者,说明VEGF165b质量浓度的相对下降与nAMD和PCV的发生和发展密切相关. Background There remains some controversy over whether polypoidal choroidal vasculopathy (PCV) represents a subtype of neovascular age-related macular degeneration (nAMD).Anti-vascular endothelial growth factor (VEGF) therapies are important in the treatment of PCV and nAMD.It has been identified that VEGF-A was differentially spliced from exons 8 and formed two isoforms families:the pro-angiogenic VEGFxxx family and the anti-angiogenic VEGFxxxb family.However,the role of the two VEGF families in PCV and nAMD was still unclear.Objective This study was to measure the contents of pro-angiogenic VEGFxxx family and the anti-angiogenic VEGFxxxb family in aqueous humor of nAMD and PCV patients and explore their effect on nAMD and PCV.Methods Thirty-four nAMD patients and 26 PCV patients were enrolled in Peking University People's Hospital during March to December,2013,and 16 age-related cataract patients served as controls.The aqueous humor samples 0.1 ml was collected before the introvitreous injection of anti-VEGF drug.The contents of pro-angiogenic VEGFxxx family and the anti-angiogenic VEGFxxx b family in the aqueous humor were measured by enzyme-linked immunosorbent assay(ELISA).Results The concentrations of VEGF in the aqueous humor in the nAMD group,PCV group and control group were (4 210.00±998.40),(387.00±51.31) and (377.40 ±69.97)pg/ml,respectively,showing a significant difference among the three groups (F =12.851,P =0.000).The concentrations of VEGF165 b in the aqueous humor in the nAMD group,PCV group and control group were (205.50±12.59),(159.40±16.25) and (347.90±29.18) pg/ml,with a significant difference among them (F=23.752,P=0.000).Compared with the control group,VEGF content in the aqueous humor was elevated and the VEGF165b content was declined in the nAMD group,and VEGF165b was lowed in the PCV group,with significant differences between them(all at P=0.000).However,no significant difference was seen in the change of VEGF between the PCV group and the control group (P=0.992).The VEGF content in the aqueous humor was higher in the nAMD group than that in the PCV group (P =0.001),but VEGF165b content was insignificantly different (P =0.097).Conclusions The downregulation of VEGFxxx b may be associated with nAMD and PCV.The different role of VEGFxxx b in the development of PCV and nAMD needs to be verified in further studies.
出处 《中华实验眼科杂志》 CAS CSCD 北大核心 2014年第12期1084-1087,共4页 Chinese Journal Of Experimental Ophthalmology
基金 北京大学人民医院研究与发展基金项目(RDB2013-21、2118000540)
关键词 血管内皮生长因子/VEGFxxx家族 VEGFxxxb家族 年龄相关性黄斑变性/新生血管性 脉络膜新生血管 脉络膜息肉样病变 Vascular endothelial growth factor/VEGFxxx family, VEGFxxx b family Age-related macular degeneration/neovascular Choroidal neovascularization Polypoidal choroidal vasculopathy
  • 相关文献

二级参考文献42

  • 1Phelps DL. Retinopathy of prematurity[J].Pediatrics in Review,1995.50-56.
  • 2Smith LE,Wesolowski E,McLellan A,Kostyk SK D'Amato R Sullivan R. Oxygen-induced retinopathy in the mouse[J].Investigative Ophthalmology & Visual Science,1994.101-111.
  • 3Witmer AN,Vrensen GF,Van Noorden C J,Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease[J].Progress in Retinal and Eye Research,2003.1-29.
  • 4Kabbinavar F,Hurwitz HI,Fehrenbacher L,Meropol NJ Novotny WF Lieberman G. Phase Ⅱ,randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer[J].Journal of Clinical Oncology,2003,(1):60-65.doi:10.1200/JCO.2003.10.066.
  • 5Yang JC,Haworth L,Sherry RM,Hwu P Schwartzentruber D J Topalian SL. A randomized trial of bevacizumab,an anti-vascular endothelial growth factor antibody,for metastatic renal cancer[J].New England Journal of Medicine,2003.427-434.
  • 6Treumer F,Roider J,Hillenkamp J. Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage[J].British Journal of Ophthalmology,2012.708-713.
  • 7El Matri L,Bouraoui R,Chebil A,Kort F,Bouladi M,Limaiem R. bevacizumab injection in patients with age-related macular degeneration associated with poor initial visual acuity[J].Journal of Ophthalmology,2012.861384.
  • 8Vallance JH. Comment on "Preclinical aspects of anti-VEGF agents for the treatment of wet AMD:ranibizumab and bevacizumab"[J].Eye (Lond),2012.167.
  • 9Ahmadieh H,Shoeibi N,Entezari M,Monshizadeh R. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients:a randomized clinical trial[J].Ophthalmology,2009.1943-1948.
  • 10di Lauro R,De Ruggiero P,di Lauro MT,Romano MR. Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy[J].Graefe's Archive for Clinical and Experimental Ophthalmology,2010.785-791.

共引文献2

同被引文献26

  • 1邹海东,张晳,许迅,汪枫桦,张世杰.上海市静安区曹家渡街道年龄相关性黄斑变性的患病率调查[J].中华眼科杂志,2005,4(1):15-19. 被引量:107
  • 2沈降,孙慧敏.年龄相关性黄斑变性的发病机制及治疗的研究[J].中国实用眼科杂志,2006,24(3):236-239. 被引量:19
  • 3邵彦,李筱荣.抗血管内皮生长因子药物治疗年龄相关性黄斑变性的现状[J].眼科,2007,16(4):282-284. 被引量:10
  • 4张歆,任百超.年龄相关性黄斑变性的治疗研究新进展[J].国际眼科杂志,2007,7(6):1674-1676. 被引量:31
  • 5CAMPOCHIARO PA, SOLOWAY P, RYAN S J, MILLER JW. The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration [ J ]. Mol Vis, 1999,5 : 34-38.
  • 6CARMELIET P, JAIN RK. Angiogenesis in cancer and other disease [J].Nature ,2000,407 ( 6801 ) :249-257.
  • 7NG EW, ADAMIS AP. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration [ J]. Can J Ophthalmo1,2005,40 ( 3 ) :352-368.
  • 8FORD KM, D' AMORE PA. Molecular regulation of vascular endothelial growth factor expression in the retinal pigment epithelium[ J]. Mol Vis ,2012,18 : 519-527.
  • 9LI X, XU G, WANG Y, XU X, LIU X, TANG S, et al. Safety and efficacy of conbercept in neovascular age-related macu- lar degeneration: Results from a 12-month randomized phase 2 study: AURORA Study [J]. Ophthalmology, 2014, 121 ( 9 ) : 1740-1747.
  • 10ZHANG M, ZHANG J, YAN M, LUO D, ZHU W, KAISER PK, et al. A phase 1 study of KHg02, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration [ J ]. Ophthalmology, 2011,118 ( 4 ) : 572-578.

引证文献2

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部